<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE GlossaryTerm >
<GlossaryTerm id="CDR0000367410"><TermName>tositumomab</TermName><TermPronunciation>(TAH-sih-TOO-moh-mab)</TermPronunciation><TermDefinition><DefinitionText>A drug used together with another drug to treat certain types of B-cell non-Hodgkin lymphoma. It is also being studied in the treatment of other types of cancer. Tositumomab binds to a protein called CD20, which is found on the surface of B cells, and may kill cancer cells. It is a type of monoclonal antibody.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></TermDefinition><MediaLink ref="CDR0000711449" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;tositumomab&quot;" language="en" id="_3"/><MediaLink ref="CDR0000711448" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;tositumomab&quot;" language="es" id="_4"/><SpanishTermName>tositumomab</SpanishTermName><SpanishTermDefinition><DefinitionText>Medicamento que se usa junto con otro medicamento para tratar ciertos tipos de linfoma no Hodgkin de células B.  También está bajo estudio para el tratamiento de otros tipos de cáncer.  El tositumomab se une con una proteína que se llama CD20, la cual se encuentra en la superficie de las células B y puede eliminar las células cancerosas.  Es un tipo de anticuerpo monoclonal.  </DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></SpanishTermDefinition><DateFirstPublished>2004-04-23</DateFirstPublished></GlossaryTerm>
